|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Respiratory Insufficiency | |||||
| Psychomotor Agitation | |||||
| 2 | More general conditions related to this trial | ||||
| Dyskinesias | |||||
| Nervous System Diseases | |||||
| Neurobehavioral Manifestations | |||||
| Neurologic Manifestations | |||||
| Psychomotor Disorders | |||||
| Respiration Disorders | |||||
| Respiratory Tract Diseases | |||||
| Signs and Symptoms | |||||
| 3 | Interventions listed in this trial | ||||
| loxapine | |||||
| 4 | More general drug interventions related to this trial | ||||
| Antipsychotic Agents | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| Dopamine Agents | |||||
| Dopamine Antagonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| Tranquilizing Agents | |||||
| 5 | Sponsors listed in this trial | ||||
| Assistance Publique - Hôpitaux de Paris | |||||